ArticleBMJ global health2025
Cost-effectiveness of different tuberculosis diagnostic approaches in Nigeria based on decision analytical modelling.
Article in BMJ global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Strategies for Tuberculosis Prevention in Healthcare Settings: A Narrative Review.Tropical medicine and infectious disease · 2025Review
- Trends in epidemiological characteristics of pulmonary tuberculosis among children and youth in Chinese mainland from 2019 to 2024: analysis of national surveillance data.BMC public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundTuberculosis (TB) remains a leading cause of morbidity and mortality in Nigeria, particularly among people living with HIV (PLWH), who face significantly higher risks of developing active TB. Conventional diagnostic methods such as sputum smear microscopy and chest radiography often fail to detect TB accurately in this population due to smear-negative presentations and atypical radiographic findings. Recent diagnostic innovations, including the Xpert MTB/RIF Ultra, TB lipoarabinomannan (TB-LAM) and TB loop-mediated isothermal amplification (TB-LAMP) tests, offer improved sensitivity and specificity, but their cost-effectiveness in resource-limited settings remains unclear.
methodsIn this economic evaluation, we combined a decision tree with cost-effectiveness analysis to compare three TB diagnostic algorithms tailored for PLWH in Nigeria: (1) Xpert MTB/RIF Ultra following chest radiography (chest X-ray; CXR), (2) TB-LAM following CXR and (3) TB-LAMP following CXR. Data on test accuracy, costs and TB prevalence were obtained from systematic reviews and meta-analyses, with costs adjusted for inflation and local purchasing power. We estimated the incremental cost-effectiveness ratios (ICERs) for the three diagnostic approaches. Sensitivity analyses were conducted to assess the robustness of results across varying input parameters.
resultsTB/LAM was found to be the most cost-effective option at a cost of US$17 per TB case detected when compared with US$20 and US$22 per TB case detected for the baseline strategy of Xpert MTB/RIF Ultra and TB-LAMP, respectively. These ICERs are consistent with willingness-to-pay thresholds set at three times Nigeria's gross domestic product (GDP) and remained robust over a wide range of costs and epidemiological parameter inputs.
conclusionAmong PLWH in Nigeria, the TB-LAM algorithm represents the most cost-effective diagnostic strategy. However, the Xpert MTB/RIF Ultra may provide additional value in settings with sufficient infrastructure and funding. This study underscores the need for tailored diagnostic approaches that balance accuracy, scalability and affordability to enhance TB detection and management in vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.